CBC Group, the healthcare-dedicated asset management firm headquartered in Singapore, has completed the strategic acquisition of global biopharmaceutical company UCB’s mature neurology and allergy business in China, in partnership with Mubadala Investment Company.
The transaction, valued at US$680 million, includes UCB’s brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site.
The well-established medicine portfolio will serve as an anchor asset as CBC builds out an integrated central nervous system (CNS) biopharma platform in China, where the market size has reached US$33 billion. Beyond strengthening CBC’s presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm’s capabilities in meeting the rising demand for neurology and allergy treatments in the wider region.
Fu Wei, Chief Executive Officer of CBC Group, said: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.
“Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation.”
Mohamed Albadr, Head of Asia at Mubadala, said: “We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system.”
Jean-Christophe Tellier, CEO at UCB, said: “In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China.”
